Track landmark observational cohorts (ADNI-4, PPMI), open pooled clinical trial trajectories (PRO-ACT ALS), Alzforum Therapeutics Pipeline alerts, and ENCALS motor neuron consensus guidelines.
Requires standard Data Use Agreement (DUA) submission on USC LONI. Approvals are typically granted to academic & research institutions in 1-3 business days.
LONI Access ApplicationOpen to Parkinson’s researchers worldwide. Free registration and DUA acceptance provide immediate download access to DaTscan tables, α-synuclein SAA metrics, and clinical logs.
PPMI Download PortalFree instant registration. Provides full longitudinal data from 23 ALS Phase II/III clinical trials with >10,700 patient trajectories for progression modeling.
PRO-ACT RegistrationClinical validation study confirms that blood-based p-tau217 assay matches CSF and Amyloid-PET diagnostic precision in identifying early Alzheimer’s pathology, potentially reshaping primary screening workflows.
Preclinical and Phase 1 biomarker readouts for novel TREM2-targeted monoclonal antibodies show sustained microglial metabolic reprogramming and enhanced plaque compaction in animal models and early human cohorts.
Large-scale pathological and biomarker synthesis of over 10,000 cases shows nearly 100% penetrance of amyloid biomarker positivity and distinct early age of symptom onset in APOE4 homozygotes.
Review of next-generation trial designs combining anti-amyloid monoclonal antibodies with microtubule-binding region (MTBR-tau) targeted antibodies to halt secondary neurodegeneration.
The ongoing ADNI-4 study expands remote digital screening, blood-based biomarker phenotyping (p-tau217, NfL, GFAP), 3T high-resolution MRI, Tau-PET (MK-6240), and Amyloid-PET in ethnically diverse cohorts.
The largest freely accessible repository of clinical trial data in ALS, containing longitudinal records of >10,700 patients from 23 Phase II/III clinical trials including ALSFRS-R functional scores, spirometry (FVC), lab chemistry, and survival outcomes.
European Network to Cure ALS framework for incorporating serum Neurofilament Light Chain (NfL) and digital respiratory monitoring into adaptive clinical trial design protocols.
Evidence-based review examining cellular mechanisms, mitochondrial preservation data, clinical trial efficacy claims, and safety profiles for combination chaperone therapies.